Posted by Michael Wonder on 27 Nov 2018
FDA promised a ‘lower-cost option’ to EpiPen, but the price isn’t any lower
27 November 2018 - Teva's alternative to Mylan's authorised generic EpiPen is no cheaper.
File this under “When is a bargain not really a bargain?”
Three months ago, the FDA approved a generic version of the EpiPen allergy-relief device and made a point of noting the new product from Teva Pharmaceutical would offer a “lower-cost option.” But Teva is not offering the sort of alternative the agency envisioned: Its $300 list price is the same that Mylan charges for its so-called authorised generic EpiPen.
